Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects

Clinical Cancer Research

Volumn 20, Issue 14, 2014, Pages 3787-3798

  Yoo, Ji Young ^a   Hurwitz, Brian S ^a,b   Bolyard, Chelsea ^c   Yu, Jun Ge ^d   Zhang, Jianying ^e   Selvendiran, Karuppaiyah ^f   Rath, Kellie S ^f   He, Shun ^g   Bailey, Zachary ⁱ   Eaves, David ⁱ   Cripe, Timothy P ^h   Parris, Deborah S ^a   Caligiuri, Michael A ^g   Yu, Jianhua ^g   Old, Matthew ^d   Kaur, Balveen ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Biomedical Science Major   (United States)

^c Integrated Biomedical Sciences Graduate Program   (United States)

^d Head and Neck Surgery   (United States)

^e Center for Biostatistics   (United States)

^f Department of Obstetrics and Gynecology   (United States)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^h THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; ESTROGEN RECEPTOR; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; ONCOLYTIC HERPES VIRUS; PROTEIN IRE1ALPHA; PROTEIN PERK; TUMOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; ONCOLYTIC VIRUS; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; ENDOPLASMIC RETICULUM STRESS; FEMALE; GLIOMA; HEAD AND NECK CANCER; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VIVO STUDY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN TARGETING; SURVIVAL TIME; UNFOLDED PROTEIN RESPONSE; VIRUS CULTURE; VIRUS REPLICATION; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; MULTIMODALITY CANCER THERAPY; NECROSIS; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; BORTEZOMIB; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; ENDOPLASMIC RETICULUM STRESS; FEMALE; HERPESVIRUS 1, HUMAN; HUMANS; MICE, NUDE; NECROSIS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PYRAZINES; UNFOLDED PROTEIN RESPONSE; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904390050     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0553     Document Type: Article

References (38)

1. Friedman GK, Pressey JG, Reddy AT, Markert JM, Gillespie GY. Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther 2009;17:1125-35.
2. Kanai R, Wakimoto H, Cheema T, Rabkin SD. Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol 2010;6:619-34.
3. Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, Franklin M, Kratzke RA, et al. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer 2009;100:1379-84.
4. Gilbert J, Lee JW, Argiris A, Haigentz M Jr, Feldman LE, Jang M, et al. Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group. Head Neck 2013;35:942-8.
5. Burch AD, Weller SK. Nuclear sequestration of cellular chaperone and proteasomal machinery during herpes simplex virus type 1 infection. J Virol 2004;78:7175-85. (Pubitemid 38781556)
6. Gross S, Catez F, Masumoto H, Lomonte P. Centromere architecture breakdown induced by the viral E3 ubiquitin ligase ICP0 protein of herpes simplex virus type 1. PLoS ONE 2012;7:e44227.
7. Horan KA, Hansen K, Jakobsen MR, Holm CK, Soby S, Unterholzner L, et al. Proteasomal degradation of herpes simplex virus capsids in macrophages releases DNA to the cytosol for recognition by DNA sensors. J Immunol 2013;190:2311-9.
8. Reid EG. Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies. Curr Opin Oncol 2011;23:482-7.
9. Yoo JY, Haseley A, Bratasz A, Chiocca EA, Zhang J, Powell K, et al. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol Ther 2012;20:287-97.
10. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 2007;99:1768-81. (Pubitemid 351767207)
11. Goodrich LD, Schaffer PA, Dorsky DI, Crumpacker CS, Parris DS. Localization of the herpes simplex virus type 1 65-kilodalton DNA-binding protein and DNA polymerase in the presence and absence of viral DNA synthesis. J Virol 1990;64:5738-49.
12. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
13. Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R, Puisieux A. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer 2008;7:50.
14. Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011;17:5311-21.
15. Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ, et al. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene 2012;31:3023-38.
16. Burnett HF, Audas TE, Liang G, Lu RR. Herpes simplex virus-1 disarms the unfolded protein response in the early stages of infection. Cell Stress Chaperones 2012;17:473-83.
17. Mathew SS, Della Selva MP, Burch AD. Modification and reorganization of the cytoprotective cellular chaperone Hsp27 during herpes simplex virus type 1 infection. J Virol 2009;83:9304-12.
18. Elsedawy NB, Russell SJ. Oncolytic vaccines. Expert Rev Vaccines 2013;12:1155-72.
19. Biologic Therapy. In:Balch C, Houghton A, Sober A, Soong S-J, editors. Cutaneous Melanoma. St. Louis: Quality Medical Publishing; 1998. p. 419-36.
20. Jurak I, Silverstein LB, Sharma M, Coen DM. Herpes simplex virus is equipped with RNA- and protein-based mechanisms to repress expression of ATRX, an effector of intrinsic immunity. J Virol 2012;86:10093-102.
21. Boutell C, Cuchet-Lourenco D, Vanni E, Orr A, Glass M, McFarlane S, et al. A viral ubiquitin ligase has substrate preferential SUMO targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence. PLoS Pathog 2011;7:e1002245.
22. Delboy MG, Nicola AV. A pre-immediate-early role for tegument ICP0 in the proteasome-dependent entry of herpes simplex virus. J Virol 2011;85:5910-8.
23. Qiu M, Chen Y, Cheng L, Chu Y, Song HY, Wu ZW. Pyrrolidine dithiocarbamate inhibits herpes simplex virus type 1 and 2 replication and its activity may be mediated through dysregulation of ubiquitin-proteasome system. J Virol 2013;87:8675-86.
24. Nagel CH, Albrecht N, Milovic-Holm K, Mariyanna L, Keyser B, Abel B, et al. Herpes simplex virus immediate-early protein ICP0 is targeted by SIAH-1 for proteasomal degradation. J Virol 2011;85:7644-57.
25. Fukushima T, Sato T, Nakamura T, Iwao H, Nakajima A, Miki M, et al. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib. Anticancer Res 2012;32:5437-40.
26. Tanaka H, Sakuma I, Hashimoto S, Takeda Y, Sakai S, Takagi T, et al. Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy: case report. J Clin Exp Hematop 2012;52:67-9.
27. di Meo N, Bergamo S, Dondas A, Trevisan G. Bortezomib and bilateral herpes zoster. Acta Dermatovenerol Alp Panonica Adriat 2012;21:21-2.
28. Khalafallah AA, Woodgate M, Koshy K, Patrick A. Ophthalmic manifestations of herpes zoster virus in patients with multiple myeloma following bone marrow transplantation. BMJ Case Rep 2013;2013.
29. Boozari B, Mundt B, Woller N, Struver N, Gurlevik E, Schache P, et al. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma. Gut 2010;59:1416-26.
30. Zou P, Kawada J, Pesnicak L, Cohen JI. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol 2007;81:10029-36. (Pubitemid 350067706)
31. Shirley CM, Chen J, Shamay M, Li H, Zahnow CA, Hayward SD, et al. Bortezomib induction of C/EBPbeta mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. Blood 2011;117:6297-303.
32. Dudek SE, Luig C, Pauli EK, Schubert U, Ludwig S. The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state. J Virol 2010;84:9439-51.
33. Yarde DN, Nace RA, Russell SJ. Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo. Exp Hematol 2013;41:1038-49.
34. Roue G, Perez-Galan P, Mozos A, Lopez-Guerra M, Xargay-Torrent S, Rosich L, et al. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood 2011;117:1270-9.
35. Burch AD, Weller SK. Herpes simplex virus type 1 DNA polymerase requires the mammalian chaperone hsp90 for proper localization to the nucleus. J Virol 2005;79:10740-9. (Pubitemid 41098613)
36. Li YH, Tao PZ, Liu YZ, Jiang JD. Geldanamycin, a ligand of heat shock protein 90, inhibits the replication of herpes simplex virus type 1 in vitro. Antimicrob Agents Chemother 2004;48:867-72.
37. Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol 2012;14:215-21.
38. Mulvey M, Arias C, Mohr I. Maintenance of endoplasmic reticulum (ER) homeostasis in herpes simplex virus type 1-infected cells through the association of a viral glycoprotein with PERK, a cellular ER stress sensor. J Virol 2007;81:3377-90. (Pubitemid 46456647)